Pharvaris N.V.
PHVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001830487
In the last 90 days, Pharvaris N.V. insiders filed 0 open-market purchases and 20 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $2.23B in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $24.5M in total
- 20
- 13F holdersQ2 2026, +15 vs. previous quarter
- 125
- 13F valueReported value at the end of Q2 2026
- $2.23B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding PHVS, Q2 2026
1 superinvestor reports holding Pharvaris N.V. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.4%
Pharvaris N.V.'s share of the portfolio
- Shares
- 3,653,310
- Value
- $126.3M
Latest insider trades
Open-market purchases and sales by Pharvaris N.V. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 25, 2026 (view filing)1:35 PM ET | Sep 23 | 2 days | Monges VivianeDirector | SSale | −12.0K | $33.05 | −$395.5K | −68.5%5.50K after | |
| Sep 24, 2026 (view filing)10:43 AM ET | Sep 22 | 2 days | Schikan Johannes Gerardus Christiaan PetrusDirector | SSale | −800 | $36.19 | −$29.0K | −0.7%115.2K after | |
| Sep 23, 2026 (view filing)10:06 AM ET | Sep 21 | 2 days | Nassif David W.CFO / CLO | SSale | −6.00K | $36.47 | −$218.8K | −5.0%114.3K after | |
| Sep 21, 2026 (view filing)4:20 PM ET | Sep 17 | 4 days | Lu PengPresident | SSale | −100.0K | $35.00 | −$3.50M | −60.6%65.0K after | |
| Sep 21, 2026 (view filing)4:18 PM ET | Sep 17 | 4 days | Schikan Johannes Gerardus Christiaan PetrusDirector | SSale | −200.0K | $35.00 | −$7.00M | −63.5%115.2K after | |
| Sep 21, 2026 (view filing)3:20 PM ET | Sep 17 | 4 days | Bjork ElisabethDirector | SSale | −52.5K | $37.89 | −$1.99M | −77.6%15.2K after | |
| Sep 21, 2026 (view filing)3:16 PM ET | Sep 17 | 4 days | Glassman RobertDirector | SSale | −14.5K | $38.56 | −$558.8K | −58.0%10.5K after | |
| Sep 21, 2026 (view filing)3:13 PM ET | Sep 17 | 4 days | Lesage AnneChief Early Development | SSale | −20.0K | $38.27 | −$765.5K | −21.3%74.0K after | |
| Sep 17, 2026 (view filing)1:22 PM ET | Sep 15 | 2 days | Abele Stefan AndreasChief Technical Ops Officer | SSale | −46.4K | $38.17 | −$1.77M | −54.3%39.1K after | 2 lots |
| Sep 17, 2026 (view filing)9:18 AM ET | Sep 15 | 2 days | Glassman RobertDirector | SSale | −8.67K | $38.27 | −$331.7K | −45.2%10.5K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Pharvaris N.V. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 6,565,272 | $227.0M | 0.01% | +280,800+4.5% | Added |
| General Atlantic LLC | 6,550,757 | $226.5M | 7.79% | −1,480,495−18.4% | Reduced |
| Foresite Capital Management IV, LLC | 4,778,581 | $165.2M | 56.95% | 00.0% | Unchanged |
| venBio Partners LLC | 4,643,430 | $160.6M | 30.92% | +4,126+0.1% | Added |
| Viking Global Investors LPSuperinvestorViking Global Investors | 3,653,310 | $126.3M | 0.36% | 00.0% | Unchanged |
| EQT Fund Management S.a r.l. | 3,424,609 | $118.4M | 13.73% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 3,376,042 | $116.7M | 1.22% | +250,000+8.0% | Added |
| Bain Capital Life Sciences Investors, LLC | 2,675,509 | $92.5M | 5.50% | 00.0% | Unchanged |
| Wellington Management Group LLP | 2,392,934 | $82.7M | 0.01% | +274,034+12.9% | Added |
| Polar Capital Holdings Plc | 2,326,389 | $80.4M | 0.23% | +1,545,373+197.9% | Added |